<DOC>
	<DOCNO>NCT00623103</DOCNO>
	<brief_summary>The purpose study provide long-term safety data rivastigmine capsule transdermal patch treatment , particular effect rivastigmine worsen underlying motor symptom Parkinson 's Disease ( PD ) , patient mild moderately severe dementia associate PD .</brief_summary>
	<brief_title>Long-term Safety Rivastigmine Capsule Patch Patients With Mild Moderately-severe Dementia Associated With Parkinson 's Disease ( PDD )</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Rivastigmine</mesh_term>
	<criteria>Diagnosis idiopathic Parkinson 's disease , accord UK Parkinson 's disease Society Brain Bank criterion Diagnosis Parkinson 's disease dementia accord Diagnostic Statistical Manual Mental Disorders , Fourth Edition ( DSMIV ) criterion , onset symptom dementia least 2 year follow first diagnosis idiopathic Parkinson 's disease Mini Mental State Examination score ≥10 ≤ 26 ( Screening Visit ) An advanced , severe , unstable disease type may interfere primary secondary variable evaluation A score 5 ( wheelchair bound bedridden ) `` '' state Modified Hoehn Yahr Staging ( UPDRS Part V ) A current diagnosis primary neurodegenerative disorder idiopathic PD A current diagnosis treatable dementia ( hypothyroidism , syphilis , vitamin B12 folate deficiency ) verify investigator cause dementia . A current diagnosis probably vascular dementia accord National Institute Neurological Disorders Stroke Association International pour la Recherche et l'Enseignement en Neurosciences ( NINDSAIREN ) criteria A current diagnosis major depressive episode accord DSMIV criterion A history stereotaxic brain surgery Parkinson 's disease A known exaggerated pharmacological sensitivity hypersensitivity drug similar rivastigmine cholinergic compound Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Parkinson 's disease dementia</keyword>
	<keyword>cholinesterase inhibitor</keyword>
	<keyword>rivastigmine</keyword>
</DOC>